Brad Margus

Brad Margus currently serves as Executive Chair of Cerevance, a clinical-stage drug development company that he co-founded and led as Chief Executive Officer from 2016 to April 2022, focused on pursuing novel targets for brain diseases. From 2009-2012, he served as co-founder and Chief Executive Officer of Envoy Therapeutics, which employed a target technology platform to discover new compounds for brain diseases, and then sold the company to Takeda Pharmaceuticals. From 2000 to 2007, Mr. Margus was the co-founder and Chief Executive Officer of Perlegen Sciences, a leader in analyzing genetic variation that raised over $250 million from investors, exceeded $100 million in revenues, and identified diagnostic markers for disease risk and drug response.